Search

Your search keyword '"Heizmann, W.R."' showing total 9 results
Start Over Author "Heizmann, W.R."
9 results on '"Heizmann, W.R."'

2. Erratum: Antimicrobials: A global alliance for optimizing their rational use in intra-abdominal infections (AGORA). [World J Emerg Surg. 11, (2016) (33)] DOI: 10.1186/s13017-016-0089-y

Author

Sartelli, M. Weber, D.G. Ruppé, E. Bassetti, M. Wright, B.J. Ansaloni, L. Catena, F. Coccolini, F. Abu-Zidan, F.M. Coimbra, R. Moore, E.E. Moore, F.A. Maier, R.V. De Waele, J.J. Kirkpatrick, A.W. Griffiths, E.A. Eckmann, C. Brink, A.J. Mazuski, J.E. May, A.K. Sawyer, R.G. Mertz, D. Montravers, P. Kumar, A. Roberts, J.A. Vincent, J.L. Watkins, R.R. Lowman, W. Spellberg, B. Abbott, I.J. Adesunkanmi, A.K. Al-Dahir, S. Al-Hasan, M.N. Agresta, F. Althani, A.A. Ansari, S. Ansumana, R. Augustin, G. Bala, M. Balogh, Z.J. Baraket, O. Bhangu, A. Beltrán, M.A. Bernhard, M. Biffl, W.L. Boermeester, M.A. Brecher, S.M. Cherry-Bukowiec, J.R. Buyne, O.R. Cainzos, M.A. Cairns, K.A. Camacho-Ortiz, A. Chandy, S.J. Che Jusoh, A. Chichom-Mefire, A. Colijn, C. Corcione, F. Cui, Y. Curcio, D. Delibegovic, S. Demetrashvili, Z. De Simone, B. Dhingra, S. Diaz, J.J. Di Carlo, I. Dillip, A. Di Saverio, S. Doyle, M.P. Dorj, G. Dogjani, A. Dupont, H. Eachempati, S.R. Enani, M.A. Egiev, V.N. Elmangory, M.M. Ferrada, P. Fitchett, J.R. Fraga, G.P. Guessennd, N. Giamarellou, H. Ghnnam, W. Gkiokas, G. Goldberg, S.R. Gomes, C.A. Gomi, H. Guzmán-Blanco, M. Haque, M. Hansen, S. Hecker, A. Heizmann, W.R. Herzog, T. Hodonou, A.M. Hong, S.K. Kafka-Ritsch, R. Kaplan, L.J. Kapoor, G. Karamarkovic, A. Kees, M.G. Kenig, J. Kiguba, R. Kim, P.K. Kluger, Y. Khokha, V. Koike, K. Kok, K.Y. Kong, V. Knox, M.C. Inaba, K. Isik, A. Iskandar, K. Ivatury, R.R. Labbate, M. Labricciosa, F.M. Laterre, P.F. Latifi, R. Lee, J.G. Lee, Y.R. Leone, M. Leppaniemi, A. Li, Y. Liang, S.Y. Loho, T. Maegele, M. Malama, S. Marei, H.E. Martin-Loeches, I. Marwah, S. Massele, A. McFarlane, M. Melo, R.B. Negoi, I. Nicolau, D.P. Nord, C.E. Ofori-Asenso, R. Omari, A.H. Ordonez, C.A. Ouadii, M. Pereira Júnior, G.A. Piazza, D. Pupelis, G. Rawson, T.M. Rems, M. Rizoli, S. Rocha, C. Sakakushev, B. Sanchez-Garcia, M. Sato, N. Segovia Lohse, H.A. Sganga, G. Siribumrungwong, B. Shelat, V.G. Soreide, K. Soto, R. Talving, P. Tilsed, J.V. Timsit, J.F. Trueba, G. Trung, N.T. Ulrych, J. van Goor, H. Vereczkei, A. Vohra, R.S. Wani, I. Uhl, W. Xiao, Y. Yuan, K.C. Zachariah, S.K. Zahar, J.R. Zakrison, T.L. Corcione, A. Melotti, R.M. Viscoli, C. Viale, P.

Subjects
lipids (amino acids, peptides, and proteins)
Abstract

The original article [1] contains an error whereby a co-author, Boris Sakakushev has their family name spelt incorrectly as 'Sakakhushev'. The authors would therefore like it known that the correct spelling of the family name is 'Sakakushev'. © The Author(s).

Published
2017

3. Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)

Author

Sartelli, M., Weber, D.G., Ruppe, E., Bassetti, M., Wright, B.J., Ansaloni, L., Catena, F., Coccolini, F., Abu-Zidan, F.M., Coimbra, R., Moore, E.E., Moore, F.A., Maier, R.V., Waele, J.J. De, Kirkpatrick, A.W., Griffiths, E.A., Eckmann, C., Brink, A.J., Mazuski, J.E., May, A.K., Sawyer, R.G., Mertz, D., Montravers, P., Kumar, A., Roberts, J.A., Vincent, J.L., Watkins, R.R., Lowman, W., Spellberg, B., Abbott, I.J., Adesunkanmi, A.K., Al-Dahir, S., Al-Hasan, M.N., Agresta, F., Althani, A.A., Ansari, S., Ansumana, R., Augustin, G., Bala, M., Balogh, Z.J., Baraket, O., Bhangu, A., Beltran, M.A., Bernhard, M., Biffl, W.L., Boermeester, M.A., Brecher, S.M., Cherry-Bukowiec, J.R., Buyne, O.R., Cainzos, M.A., Cairns, K.A., Camacho-Ortiz, A., Chandy, S.J., Jusoh, A. Che, Chichom-Mefire, A., Colijn, C., Corcione, F., Cui, Y., Curcio, D., Delibegovic, S., Demetrashvili, Z., Simone, B. De, Dhingra, S., Diaz, J.J., Carlo, I. Di, Dillip, A., Saverio, S. Di, Doyle, M.P., Dorj, G., Dogjani, A., Dupont, H., Eachempati, S.R., Enani, M.A., Egiev, V.N., Elmangory, M.M., Ferrada, P., Fitchett, J.R., Fraga, G.P., Guessennd, N., Giamarellou, H., Ghnnam, W., Gkiokas, G., Goldberg, S.R., Gomes, C.A., Gomi, H., Guzman-Blanco, M., Haque, M., Hansen, S., Hecker, A., Heizmann, W.R., Herzog, T., Hodonou, A.M., Hong, S.K., Kafka-Ritsch, R., Kaplan, L.J., Kapoor, G., Karamarkovic, A., Kees, M.G., Kenig, J., Kiguba, R., et al., Sartelli, M., Weber, D.G., Ruppe, E., Bassetti, M., Wright, B.J., Ansaloni, L., Catena, F., Coccolini, F., Abu-Zidan, F.M., Coimbra, R., Moore, E.E., Moore, F.A., Maier, R.V., Waele, J.J. De, Kirkpatrick, A.W., Griffiths, E.A., Eckmann, C., Brink, A.J., Mazuski, J.E., May, A.K., Sawyer, R.G., Mertz, D., Montravers, P., Kumar, A., Roberts, J.A., Vincent, J.L., Watkins, R.R., Lowman, W., Spellberg, B., Abbott, I.J., Adesunkanmi, A.K., Al-Dahir, S., Al-Hasan, M.N., Agresta, F., Althani, A.A., Ansari, S., Ansumana, R., Augustin, G., Bala, M., Balogh, Z.J., Baraket, O., Bhangu, A., Beltran, M.A., Bernhard, M., Biffl, W.L., Boermeester, M.A., Brecher, S.M., Cherry-Bukowiec, J.R., Buyne, O.R., Cainzos, M.A., Cairns, K.A., Camacho-Ortiz, A., Chandy, S.J., Jusoh, A. Che, Chichom-Mefire, A., Colijn, C., Corcione, F., Cui, Y., Curcio, D., Delibegovic, S., Demetrashvili, Z., Simone, B. De, Dhingra, S., Diaz, J.J., Carlo, I. Di, Dillip, A., Saverio, S. Di, Doyle, M.P., Dorj, G., Dogjani, A., Dupont, H., Eachempati, S.R., Enani, M.A., Egiev, V.N., Elmangory, M.M., Ferrada, P., Fitchett, J.R., Fraga, G.P., Guessennd, N., Giamarellou, H., Ghnnam, W., Gkiokas, G., Goldberg, S.R., Gomes, C.A., Gomi, H., Guzman-Blanco, M., Haque, M., Hansen, S., Hecker, A., Heizmann, W.R., Herzog, T., Hodonou, A.M., Hong, S.K., Kafka-Ritsch, R., Kaplan, L.J., Kapoor, G., Karamarkovic, A., Kees, M.G., Kenig, J., Kiguba, R., and et al.

Abstract

Contains fulltext : 168575.pdf (publisher's version ) (Open Access), Intra-abdominal infections (IAI) are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients. The cornerstones in the management of complicated IAIs are timely effective source control with appropriate antimicrobial therapy. Empiric antimicrobial therapy is important in the management of intra-abdominal infections and must be broad enough to cover all likely organisms because inappropriate initial antimicrobial therapy is associated with poor patient outcomes and the development of bacterial resistance. The overuse of antimicrobials is widely accepted as a major driver of some emerging infections (such as C. difficile), the selection of resistant pathogens in individual patients, and for the continued development of antimicrobial resistance globally. The growing emergence of multi-drug resistant organisms and the limited development of new agents available to counteract them have caused an impending crisis with alarming implications, especially with regards to Gram-negative bacteria. An international task force from 79 different countries has joined this project by sharing a document on the rational use of antimicrobials for patients with IAIs. The project has been termed AGORA (Antimicrobials: A Global Alliance for Optimizing their Rational Use in Intra-Abdominal Infections). The authors hope that AGORA, involving many of the world's leading experts, can actively raise awareness in health workers and can improve prescribing behavior in treating IAIs.

Published
2016

8. Sulbactam in combination with mezlocillin, piperacillin or cefotaxime: clinical and bacteriological findings in the treatment of serious bacterial infections

Author

Manncke, K., Springsklee, M., Heizmann, W.R., and Sonntag, H.G.

Abstract

An open, multicentre study was performed in hospital in-patients at a total of 12 German hospitals to investigate the efficacy and tolerability of sulbactam combined with mezlocillin, piperacillin or cefotaxime in severe bacterial infections. A total of 155 patients were recruited into the study, of whom 48 were suffering from respiratory tract infections, 66 from intra-abdominal infections, 34 from skin/soft tissue infections including postoperative wound infections, and five from complicated urinary tract infections. Fifty-five patients intravenously received 4 g mezlocillin and 1 g sulbactam three times daily, 52 received 4 g piperacillin and 1 g sulbactam three times daily, and 48 received 2 g cefotaxime and 1 g sulbactam three times daily. The antibiotic and sulbactam combination was administered in all cases by rapid intravenous infusion of both components together, over 20 min. The mean duration of treatment was 20 days. The criteria used to define the outcome of treatment as successful were clinical cure (complete disappearance of the signs and symptoms of infection seen before the start of treatment) or improvement (appreciable diminution or partial resolution of the initial signs and symptoms, no further antibiotic therapy required) and the elimination of the organisms isolated before the start of the study. Of the 153 clinically evaluable patient, 141 (92%) were classed as responders (a cure was obtained in 98 cases and improvement in 43 cases). No response to the study medication was seen in 12 patients (7.8%). The response rates of the combined antibiotic-sulbactam preparations were 91% for mezlocillin/sulbactam, 92% for piperacillin/sulbactam, and 93% for cefotaxime/sulbactam. These response rates are almost identical. A total of 106 patients (68.4%) were bacteriologically evaluable; a total of 192 bacterial organisms were identified in these patients before the start of treatment. Mixed infection was present in 55 patients. The causative organism initially isolated was eliminated in 96 patients (90%), accounting for 180 of 192 strains (94%). Persistence of the causative organism (12 strains) was seen in eight patients (7.6%). Superinfection (four strains) was seen in two patients (1.9%). The study medication was well tolerated; adverse drug effects were seen in only five patients (3.3%). Treatment was discontinued in one patient because of the adverse effect (exanthema). The combination of the β-lactamase inhibitor sulbactam and a ureidopenicillin or cefotaxime was highly effiacious in patients with severe bacterial infections investigated in this study. The availability of sulbactam as a single-agent preparation opens up new avenues for flexible and cost-effective antibiotic therapy and is a valuable contribution to the control of bacterial resistance.

Published
1995
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results